FINANCIAL DISCLOSURES
 None BACKGROUND  Tigecycline is a broad-spectrum glycilcycline antibiotic first FDA-approved in 2005 for treatment of complicated skin and soft-tissue infections and complicated intra-abdominal infections  Tigecycline inhibits Clostridium difficile toxin production and sporulation in vitro  Tigecycline has been used off-label for treatment of refractory or severe CDAD  In September of 2013, the FDA issued a warning regarding increased risk of death when tigecycline was used for treatment of FDA-approved or nonapproved uses  Severe CDAD was defined by a scoring system derived from the Hines VA Clostridium difficile severity index score. Patients with a score of 3 or greater were included in the study.
METHODS: IDENTIFICATION OF SEVERE CDI
• Documented fever ≥38• C within 3 days of diagnosis: 1 point • Hypotension (systolic blood pressure <100 mm Hg on any single read within 3 days of diagnosis): 1 point • Leukocytosis
• WBC ≥15,000, <30 
